Surrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference
-- Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine --
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will participate in a fireside chat at the Morgan Stanley 18th Annual Healthcare Conference. The fireside chat will begin at 8:45 a.m. Eastern on Friday, September 18, 2020. The public may access the event live via webcast at: https://morganstanley.webcasts.com/starthere.jsp?ei=1362365&tp_key=4efb3f9b6c. An archived replay will be available following the event for 90 days.
About Wnt Signaling
About Surrozen’s Proprietary Antibody Platforms and Harnessing Wnt Signaling
About Surrozen Preclinical Candidates
SZN-1326 is the first development candidate designed using Surrozen’s SWAP platform. SZN-1326 targets the Wnt-signaling pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis, SZN-1326 has been shown to activate Wnt signaling in the intestine, stimulate intestinal epithelial regeneration, and reduce disease activity. Surrozen will develop SZN-1326 for moderate to severe inflammatory bowel disease.
Investors/Partners/Media: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. firstname.lastname@example.org
ROI Use Case
Competitive Advantages of Edge Analytics